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Anti-centromere antibody exhibits 
specific distribution levels among 
anti-nuclear antibodies and may 
characterize a distinct subset in 
rheumatoid arthritis
Nobuo Kuramoto1, Koichiro Ohmura1, Katsunori Ikari2, Koichiro Yano2, Moritoshi Furu3, 
Noriyuki Yamakawa1, Motomu Hashimoto3, Hiromu Ito3, Takao Fujii1, Kosaku Murakami1, 
Ran Nakashima1, Yoshitaka Imura1, Naoichiro Yukawa1, Hajime Yoshifuji1, Atsuo Taniguchi2, 
Shigeki Momohara2, Hisashi Yamanaka2, Fumihiko Matsuda4, Tsuneyo Mimori1,3 &  
Chikashi Terao4,5,6,7,8
Anti-centromere antibody (ACA) is one of the classical anti-nuclear antibody (ANA) staining patterns. 
However, characteristics of ACA in comparison with the other ANA patterns and clinical features of 
ACA-positive subjects have not been elucidated. Here, we examined all ANA patterns by indirect 
immunofluorescence for 859 rheumatoid arthritis (RA) patients. Together with the ANA data of 
9,575 healthy volunteers, we compared distributions of the ANA levels. ACA was the only ANA that 
demonstrated a definite bimodal distribution of levels. ACA showed significantly higher levels than 
the other ANA staining patterns in both RA and healthy population (p < 0.0001). ACA-positivity was 
associated with old age and was observed more in females. We further recruited another cohort of 
3,353 RA patients and confirmed the findings. ACA was also associated with Raynaud’s phenomenon 
(p = 6.8 × 10−11) in RA. As a conclusion, ACA displays a specific ANA staining pattern with a bimodal 
distribution, and ACA-positive RA may constitute a distinct subset with specific clinical features.
Anti-centromere antibody (ACA) is a type of anti-nuclear antibody (ANA) detected by indirect immunofluorescence 
displaying a centromeric pattern (discrete speckled pattern)1. Although ACA has been considered specific for lim-
ited cutaneous systemic sclerosis (SSc)2, it is occasionally detected in patients with primary biliary cirrhosis (PBC) 
and primary Sjögren’s syndrome (SS) with various range of positivity (11 to 27% and 3.7 to 27%, respectively)3–5. 
In some reports, a subset of patients with rheumatoid arthritis (RA) were also positive for ACA6, 7, 
as well as healthy subjects8.
We previously quantified ANA in 9,575 healthy subjects without connective tissue diseases and reported that 
87 individuals (0.91%) of healthy subjects were positive for ACA8. ACA was associated with old age and was 
observed more in females in the healthy subjects. After reporting these findings, we noticed that for other ANA 
staining patterns most of Ab-positive subjects were enriched by less than 1:160, but subjects positive for ACA 
were enriched at higher titer levels, by more than 1:640. Thus, we hypothesized that ACA might exhibit a specific 
distribution where most ACA-positive subjects had high titer levels. Some previous studies have reported that 
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patients with rheumatic diseases might have high levels of ACA9, but they had no comprehensive data for ANA 
and failed to reach a clear conclusion supported by statistical significance.
In this study, we compared the distribution level of ACA with that of the other staining patterns, namely, 
speckled, homogeneous, nucleolar and cytoplasmic patterns in healthy subjects, and in RA patients. We also 
analyzed correlates and clinical features of ACA-positivity in patients with RA.
Results
ACA demonstrates higher levels than the other ANA staining patterns and shows a bimodal 
distribution. We took advantage of the ANA data of 9,575 subjects from our previous report and analyzed 
the distribution of ANA levels in each staining pattern. In the 4,332 healthy subjects who were positive for ANA 
(Fig. 1A), only the discrete speckled pattern (ACA) showed a high-level-skewed distribution (Supplementary 
Figure 1A). When we compared the levels between all the staining patterns, ACA showed higher levels than all 
other staining patterns (p < 0.0001, Fig. 1A).
We confirmed this finding in patients with RA using data of 859 RA patients in the Kyoto University 
Rheumatoid Arthritis Management Alliance (KURAMA) cohort without SSc (p < 0.0001, Fig. 1B and Fig. 2). 657 
subjects (76.5%) were positive for ANA and 25 patients (2.9%) were ACA-positive. 96.0% of RA patients positive 
ACA showed levels of 1:320 or higher, and less than 14.1% of patients with RA positive for the other staining 
patterns showed the comparable levels (Supplementary Figure 1B). Chi-squared test between ACA and speckled 
pattern which is the most representative staining pattern of ANA also showed significant high-level-skewed dis-
tribution of ACA in both healthy subjects and RA patients (Supplementary Table 1). Sixteen out of the 25 patients 
had data of enzyme-linked immunosorbent assay (ELISA) for ACA and all were positive. This distribution was 
consistent regardless of sex in the healthy population (Supplementary Figure 2). Only one male was positive for 
ACA in the RA subjects.
Figure 1. Distribution of ANA levels by each staining pattern. The ANA levels were log-transformed 
(log2(level/40) + 1) and compared by Wilcoxon rank sum test. ACA showed a significantly higher level than the 
other staining patterns in (A) healthy subjects, and (B) RA patients in the KURAMA cohort (p < 0.0001). Most 
subjects were positive for multiple ANA staining patterns.
Figure 2. A flow chart of study participants with RA in the KURAMA cohort. From 1,187 RA patients, 307 
patients without ANA data were excluded. Then we excluded 21 patients overlapping with SSc. The remaining 
859 patients were used to compare ACA-positive patients with ACA-negative patients. We analyzed 657 subjects 
positive for ANA to compare the level of ANA among each staining pattern.
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Clinical features of ACA-positive RA patients. We analyzed the clinical features of ACA-positive 
patients with RA (Fig. 2 and Table 1). The ACA-positive group was older and tended to be prevalently female 
(96.0% vs 78.7%) (p = 0.0042 and 0.042, respectively, Table 1). We confirmed the association between ACA and 
old age in female RA subjects (Supplementary Table 2). ACA positivity was associated with low positivity of 
rheumatoid factor (RF) and anti-cyclic citrullinated protein antibody (ACPA), representative antibodies found in 
patients with RA (Table 1). No significant differences were observed in other clinical manifestations.
We analyzed 3,353 RA patients without SSc whose ANA data were available from the Institute of 
Rheumatology, Rheumatoid Arthritis (IORRA) cohort to confirm the associations. 61 subjects of the 3,353 
patients (1.8%) were positive for ACA. The association between ACA-positivity and old age and females were 
replicated (p = 6.4 × 10−5 and p = 0.0089, respectively, Table 1). The associations between ACA and RA-related 
autoantibodies were not replicated (Table 1).
We confirmed these observations in the analysis of ANA-positive RA (Table 2).
We further investigated the associations between ACA-positivity and complications observed in RA. 
Raynaud’s phenomenon and secondary SS were significantly associated with ACA-positivity (p = 6.8 × 10−11 and 
0.0047, OR:19.7 (95% CI:8.55–46.7) and 7.37 (2.02–21.5), respectively, Table 3). Logistic regression analysis with 
response variate of ACA and covariates of age and sex confirmed significant associations between ACA and 
Raynaud’s phenomenon and secondary SS (Supplementary Table 3). Interstitial pneumonia and complication of 
PBC showed tendency of associations with ACA-positivity (Table 3). Again, we confirmed these observations in 
the analysis of ANA-positive RA (Table 4). These findings indicate that ACA-positive RA patients tend to present 
with phenotypes related with SSc, even if they do not suffer from SSc. We did not have sufficient data concerning 
other SSc-associated phenotypes. There was no clinical information available from the IORRA cohort.
Analysis of HLA-DRB1 alleles susceptible to ACA positivity. HLA-DRB1 is the strongest susceptibil-
ity gene to RA10. We searched for HLA-DRB1 alleles associated with ACA-positivity in a total of 23 ACA-positive 
and 818 ACA-negative RA. The combined analysis of the two cohorts showed that DRB1*10:01 tended to be 
associated with ACA-positivity, although it did not reach a significant level after Bonferroni’s correction 
(p = 0.034, Table 5). Imputation of HLA-DRB1 alleles in our previous study using healthy subjects did not iden-
tify DRB1*10:01 as a significant allele (data not shown)8. Analysis on shared epitope (SE), a common allelic group 
showing associations with RA susceptibility, did not show a significant difference (Supplementary Table 4). When 
we analyzed HLA-DRB1 serotypes, we did not find significant associations (Supplementary Table 5). Power cal-
culation suggested that HLA-DRB1 alleles with odds ratio of more than 5 and allele frequency of more than 0.1 
were not likely (Supplementary Table 6).
Analysis of Total Sharp Score (TSS) data in the ACA-positive RA patients. Lastly, we analyzed an 
association between ACA and bone destruction in RA by multivariate analysis. While TSS in the ACA-positive 
group had a tendency to be high in the KURAMA cohort, we could not replicate the tendency in the IORRA 
cohort (Table 6).
KURAMA IORRA KURAMA + IORRA
ACA +  
(n = 25)
ACA −  
(n = 834) P Value
OR  
(95% CI)
ACA +  
(n = 61)
ACA −  
(n = 3292) P Value
OR  
(95% CI)
ACA +  
(n = 86)
ACA −  
(n = 4126) P Value
OR  
(95% CI)














onset 56.6 ± 16.2 49.4 ± 16.0 0.038 46.0 ± 15.6 45.3 ± 15.0 0.75 49.2 ± 17.1 46.2 ± 15.3 0.085
RA 
duration 11.9 ± 8.2 11.3 ± 10.7 0.74 18.6 ± 13.6 11.6 ± 10.8 2.8 × 10
−5 16.6 ± 12.6 11.6 ± 10.8 5.5 × 10−5
RF, % 56.0 76.7 0.0029 0.39 (0.17–0.89) 83.6 84.0 0.86
0.94 
(0.51–2.05) 75.6 82.5 0.097
0.66 
(0.41–1.11)
ACPA, % 66.7 78.1 0.21 0.56 (0.24–1.41) 86.8 80.9 0.38
1.56 
(0.75–3.79) 80.5 80.3 0.95
1.02 
(0.59–1.86)
Stage 2.89 ± 1.36 2.52 ± 1.17 0.38 NA NA NA NA
Class 2.11 ± 0.78 1.85 ± 0.77 0.35 NA NA NA NA
TSS 174.5 ± 149.1 103.3 ± 102.1 0.35 11.5 ± 15.2 22.6 ± 24.8 0.58 35.4 ± 79.5 44.5 ± 67.4 0.24
DAS28 ESR 4.34 ± 1.93 2.97 ± 1.27 0.086 NA NA NA NA
MTX, % 60.0 66.5 0.52 0.76 (0.34–1.76) 55.7 69.6 0.025
0.55 
(0.33–0.92) 57.0 69.0 0.018
0.60 
(0.39–0.92)
Bio, % 64.0 40.2 0.022 2.65 (1.18–6.32) 31.1 28.1 0.66
1.15 
(0.65–1.97) 40.7 30.6 0..044
1.56 
(1.00–2.40)
Table 1. Clinical features of ACA-positive RA patients. KURAMA, Kyoto University Rheumatoid Arthritis 
Management Alliance; IORRA, Institute of Rheumatology, Rheumatoid arthritis; ACA, anti-centromere 
antibody; OR, odds ratio; 95% CI, 95% confidence interval; RA, rheumatoid arthritis; TSS, total sharp score; 
DAS, disease activity score; ESR, erythrocyte sedimentation rate; MTX, methotrexate; Bio: biologic therapy; 
NA, not applicable. mean ± standard deviation is indicated for quantitative traits.
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Discussion
There are some studies reporting observation of high levels of ACA7, 9 but to the best of our knowledge, none of 
the studies support their observation with statistical significance. There are a few published studies on the clin-
ical aspects of ACA-positive patients11. ACA is reported to have high negative predictive value for CREST syn-
drome12, but it is a rarity to focus on relationship between ACA and SSc-related phenotypes in non-SSc patients. 
This is the first comprehensive study to statistically demonstrate the higher levels of ACA compared to the other 
staining patterns of ANA. ACA-positive subjects are generally older and prevalently female. We also revealed 
the clinical characteristics of ACA-positive patients of RA. ACA-positive RA patients presented with Raynaud’s 
phenomenon more frequently than ACA-negative RA patients. These findings suggest that ACA seldom presents 
as false-positive and could thus serve as a potential biomarker with high specificity. This study is a retrospective 
study and the limited number of subjects positive for ACA makes it difficult to argue clinical usefulness of the 
current findings. Future experimental validation and elucidation of mechanisms of ACA production together 
with prospective clinical studies would be necessary.
KURAMA IORRA KURAMA + IORRA
ACA +  
(n = 25)
ACA –  
ANA +  
(n = 632) P Value
OR  
(95% CI)
ACA +  
(n = 61)
ACA −  
ANA + 
(n = 2313) P Value
OR  
(95% CI)
ACA +  
(n = 86)
ACA −  
ANA +  
(n = 2945) P Value
OR  
(95% CI)
Age 68.8 ± 11.9 60.7 ± 14.2 0.0026 64.8 ± 13.8 56.1 ± 14.8 8.9 × 10−6 65.9 ± 13.3 57.1 ± 14.7 6.1 × 10−8








3.49 12.6 0.012 0.25  (0.062–0.68)
Age at 
onset 56.6 ± 16.2 49.6 ± 15.6 0.033 46.0 ± 16.6 44.1 ± 14.9 0.36 49.2 ± 17.1 45.1 ± 15.2 0.021
RA 
duration 11.9 ± 8.2 11.6 ± 10.4 0.64 18.6 ± 13.5 11.8 ± 10.9 5.0 × 10
−5 16.6 ± 12.6 11.8 ± 10.8 0.00014
RF, % 56.0 81.3 0.0011 0.30 (0.13–0.69) 83.6 88.5 0.24
0.66 
(0.34–1.40) 75.6 87.0 0.0023 0.46 (0.29–0.79)
ACPA, % 66.7 82.0 0.088 0.48 (0.20–1.20) 86.8 86.0 0.86
0.93 
(0.38–1.96) 80.5 85.0 0.27 0.73 (0.42–1.33)
TSS 174.5 ± 149.1 105.5 ± 104.3 0.36 11.5 ± 15.2 23.6 ± 24.6 0.70 35.5 ± 79.5 48.2 ± 71.4 0.37
MTX, % 60.0 67.9 0.47 0.74 (0.33–1.73) 55.7 69.1 0.027
0.56 
(0.34–0.95) 57.0 68.8 0.020 0.60 (0.39–0.93)
Bio, % 64.0 45.4 0.035 2.39 (1.06–5.73) 31.1 28.9 0.71
0.90 
(0.53–1.59) 40.7 32.5 0.11 1.43 (0.91–2.20)
Table 2. Clinical features of ACA-positive RA patients among ANA-positive subjects. KURAMA, Kyoto 
University Rheumatoid Arthritis Management Alliance; IORRA, Institute of Rheumatology, Rheumatoid 
arthritis; ACA, anti-centromere antibody; OR, odds ratio; 95% CI, 95% confidence interval; RA, rheumatoid 
arthritis; TSS, total sharp score; DAS, disease activity score; ESR, erythrocyte sedimentation rate; MTX, 
methotrexate; Bio: biologic therapy. mean ± standard deviation is indicated for quantitative traits.
ACA + (n = 25) ACA − (n = 834) p Value OR (95% CI)
Raynaud’s phenomenon, 
% 56.0 6.06 6.8 × 10
−11 19.7 (8.55–46.7)
Interstitial pneumonia, % 20.0 10.6 0.18 2.12 (0.69–5.39)
Secondary SS, % 16.0 2.52 0.0047 7.37 (2.02–21.5)
PBC, % 4.0 0.25 0.087 17.0 (0.77–182.9)
Table 3. Clinical manifestations and complications in ACA-positive RA patients. ACA, anti-centromere antibody; 
OR, odds ratio; 95% CI, 95% confidence interval; SS, Sjögren’s syndrome; PBC, Primary biliary cirrhosis.
ACA + (n = 25) ACA − ANA + (n = 632) p Value OR (95% CI)
Raynaud’s 
phenomenon, % 56.0 7.8 6.86 × 10
−16 15.3 (6.62–36.4)
Interstitial 
pneumonia, % 20.0 10.8 0.16 2.07 (0.67–5.31)
Secondary SS, % 16.0 3.3 0.0036 5.54 (1.52–16.2)
PBC, % 4.0 0.32 0.041 12.8 (0.58–137.6)
Table 4. Clinical manifestations and complications in ACA-positive RA patients among ANA-positive RA 
subjects. ACA, anti-centromere antibody;OR, odds ratio; 95% CI, 95% confidence interval; SS, Sjögren’s 
syndrome; PBC: Primary biliary cirrhosis.
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Our results suggest that ACA-positive RA might be a distinct subset. ACA is also frequently positive in 
patients with SSc and it is regarded as a subset of the disease. The onset age of ACA-positive SS is high4 and the 
patients of SS often have Raynaud’s phenomenon4, 13–15. Since these features are the same as the findings in the 
current study and SSc was not included in this study, these characteristics might be the common features of 
ACA-positive subjects. Interstitial pneumonia is often complicated with SSc. While there have not been any pub-
lished reports showing that interstitial pneumonia is frequently seen in ACA-positive patients with SSc, our study 
suggested that we should be aware of interstitial pneumonia in ACA-positive RA patients even without SSc. This 
study also suggests the possibility that the phenotypes found in patients with limited SSc might be associated with 
the presence of ACA and not necessarily with SSc itself.
We failed to confirm that ACA-positivity is another risk factor of bone destruction. We could not find suscep-
tibility HLA-DRB1 alleles to ACA positivity. Since this study is still underpowered especially for the number of 
ACA-positive RA subjects, we cannot draw any conclusions regarding associations between ACA positivity and 
joint destruction or HLA-DRB1 alleles. HLA-DRB1*04:05 is a susceptibility allele to ANA8 and exhibits strong 
association with the development of RA and joint destruction10. Thus, there is a possibility that ACA is associated 
with DRB1 alleles and joint destruction. Increasing the number of subjects would clarify these aspects in the 
future.
While experimental validation for the association between ACA and SSc-related phenotypes is beyond 
the scope of this study, it would be interesting to inject ACA purified from patients positive for ACA into 
experimental animals such as monkeys and observe whether they develop SSc-related phenotypes including 
Raynaud’s phenomenon.
Conclusions
Our study demonstrated that the level of ACA showed a bimodal distribution and is significantly higher than the 
other staining patterns of ANA in both healthy subjects and RA patients. The current results also suggested that 
the ACA-positive RA patients may constitute a definite subset. We could not elucidate whether ACA-positivity is 
a risk factor of bone destruction. Further large-scale studies would be essential to identify specific susceptibility 
gene(s) to ACA-positivity.
KURAMA IORRA KURAMA + IORRA
ACA +  
(n = 12)
ACA −  
(n = 348) P Value
OR  
(95% CI)
ACA +  
(n = 11)
ACA −  
(n = 470) P Value
OR  
(95% CI)
ACA +  
(n = 23)
ACA −  
(n = 818) P Value OR (95% CI)
DRB1*01:01 0.083 0.070 0.88 1.34 (0.20–5.29) 0.14 0.073 0.94 1.22 (0.18–4.74) 0.11 0.072 0.50 1.78 (0.58–4.56)
DRB1*04:01 0.00 0.033 0.48 0.00 (0.00–3.14) 0.045 0.028 0.39 0.00 (0.00–2.94) 0.022 0.030 0.94 0.78 (0.043–3.84)
DRB1*04:03 0.042 0.02 0.51 2.17 (0.11–12.4) 0.00 0.016 0.56 0.00 (0.00–6.54) 0.022 0.018 0.95 1.33 (0.073–5.71)
DRB1*04:04 0.00 0.0029 0.71 0.00 (0.00–49.1) 0.00 0.0043 0.75 0.00 (0.00–25.5) 0.00 0.0037 0.68 0.00 (0.00–13.8)
DRB1*04:05 0.29 0.26 0.84 1.03 (0.29–3.48) 0.41 0.27 0.19 1.11 (0.31–4.06) 0.35 0.27 0.17 1.16 (0.47–2.87)
DRB1*04:06 0.042 0.019 0.48 2.34 (0.12–13.5) 0.045 0.021 0.035 4.74 (0.70–19.6) 0.043 0.020 0.27 2.27 (0.35–8.18)
DRB1*04:07 0.042 0.0057 0.14 7.82 (0.38–58.6) 0.00 0.0021 0.82 0.00 (0.00–66.2) 0.022 0.0037 0.060 6.15 (0.32–38.1)
DRB1*04:10 0.042 0.019 0.48 2.34 (0.12–13.5) 0.045 0.019 0.43 2.28 (0.12–12.7) 0.043 0.019 0.23 2.42 (0.38–8.76)
DRB1*08:01 0.00 0.0014 0.79 0.00 (0.00–175.0) 0.00 0.00 — — 0.00 0.00061 0.87 0.00 (0.00–211.0)
DRB1*08:02 0.00 0.023 0.29 0.00 (0.00-3.82) 0.00 0.014 0.56 0.00 (0.00–6.54) 0.00 0.018 0.36 0.00 (0.00–2.45)
DRB1*08:03 0.13 0.050 0.26 3.39 (0.72–12.0) 0.045 0.041 0.99 1.06 (0.057–5.68) 0.087 0.045 0.30 2.31 (0.66–6.37)
DRB1*09:01 0.17 0.16 0.59 1.37 (0.36–4.45) 0.091 0.19 0.039 0.00 (0.00–0.55) 0.13 0.18 0.57 0.94 (0.34–2.29)
DRB1*10:01 0.083 0.0072 0.024 22.9 (2.80-154.1) 0.00 0.0053 0.72 0.00 (0.00–19.4) 0.043 0.00061 0.034 9.63 (1.40–41.4)
DRB1*11:01 0.00 0.02 0.33 0.00 (0.00–4.43) 0.00 0.021 0.47 0.00 (0.00–4.08) 0.00 0.021 0.32 0.00 (0.00–2.07)
DRB1*12:01 0.042 0.029 0.72 1.49 (0.080–8.27) 0.00 0.028 0.39 0.00 (0.00–2.94) 0.043 0.028 0.53 1.60 (0.25–5.68)
DRB1*12:02 0.00 0.023 0.29 0.00 (0.00–3.82) 0.00 0.022 0.45 0.00 (0.00–3.87) 0.00 0.023 0.30 0.00 (0.00–1.89)
DRB1*13:01 0.00 0.0014 0.79 0.00 (0.00–175.0) 0.00 0.0011 0.87 0.00 (0.00–235.8) 0.00 0.0012 0.81 0.00 (0.00–58.8)
DRB1*13:02 0.00 0.034 0.46 0.00 (0.00–2.97) 0.00 0.034 0.65 0.00 (0.00–2.71) 0.022 0.034 0.90 0.73 (0.040–3.57)
DRB1*14:01 0.00 0.014 0.41 0.00 (0.00–6.44) 0.00 0.0085 0.65 0.00 (0.00–11.2) 0.00 0.011 0.47 0.00 (0.00–4.08)
DRB1*14:02 0.00 0.00 — — 0.00 0.0011 0.87 0.00 (0.00–235.8) 0.00 0.00061 0.87 0.00 (0.00–211.0)
DRB1*14:03 0.00 0.011 0.46 0.00 (0.00–8.29) 0.00 0.014 0.56 0.00 (0.00–6.54) 0.00 0.013 0.44 0.00 (0.00–3.46)
DRB1*14:05 0.00 0.013 0.43 0.00 (0.00–7.25) 0.00 0.012 0.59 0.00 (0.00–7.86) 0.00 0.012 0.45 0.00 (0.00–3.64)
DRB1*14:06 0.00 0.011 0.46 0.00 (0.00–8.29) 0.00 0.013 0.87 0.00 (0.00–8.72) 0.00 0.012 0.76 0.00 (0.00–4.08)
DRB1*14:54 0.00 0.011 0.46 0.00 (0.00–8.29) 0.00 0.0064 0.025 0.12 (0.017–2.37) 0.00 0.0085 0.53 0.00 (0.00–5.35)
DRB1*15:01 0.00 0.056 0.26 0.00 (0.00–1.49) 0.00 0.048 0.14 0.28 (0.080–1.30) 0.00 0.051 0.28 0.00 (0.00–0.81)
DRB1*15:02 0.00 0.093 0.10 0.00 (0.00–0.89) 0.045 0.093 0.68 0.42 (0.023–2.21) 0.022 0.093 0.24 0.22 (0.012–1.05)
DRB1*16:02 0.042 0.0086 0.22 5.18 (0.26–34.2) 0.00 0.012 0.57 0.00 (0.00–7.14) 0.043 0.010 0.035 4.49 (0.68–17.1)
Table 5. Association of HLA-DRB1 alleles with ACA-positivity. KURAMA, Kyoto University Rheumatoid 
Arthritis Management Alliance; IORRA, Institute of Rheumatology, Rheumatoid arthritis; ACA, anti-
centromere antibody; OR, odds ratio; 95% CI, 95% confidence interval.
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Patients and Methods
Study Population. The data collection and statistical analyses in this study were approved by the ethic com-
mittee in Kyoto University (Kyoto 606-8507, Japan) and Tokyo Women’s University (Tokyo 162-8666, Japan) and 
adhered to the ethical guidelines for clinical studies in Japan.
A total of 9,575 Japanese healthy volunteers in our previous report in which we had excluded subjects sus-
pected of having connective tissue diseases were recruited for analyzing the distribution of the levels of each ANA 
staining pattern8.
We screened 1,187 RA patients from the KURAMA cohort of Kyoto University for the availability of 
ANA data. 880 patients had ANA data, but we excluded 21 subjects since they fulfilled American college of 
Rheumatology (ACR) criteria for SSc in 1980 and ACR/European League Against Rheumatism (EULAR) criteria 
for SSc in 2013. As a result, 859 RA patients were included in the analysis (Fig. 2). When we compared the ANA 
level of each staining pattern, we analyzed 657 RA patients who were positive for ANA (details are shown in 
Fig. 2).
For validation study, we recruited 3,404 patients with RA whose ANA data were available from the IORRA 
cohort of Tokyo Woman’s Medical University. We excluded 51 patients who had possibilities of SSc. As a result, 
3,353 patients were analyzed for the validation study.
All of the patients fulfilled the ACR revised criteria for RA in 198716 or the ACR and EULAR classification 
criteria for RA in 201017, 18.
Written informed consent was obtained from all of the study participants except for a limited number of the 
KURAMA subjects. For these patients, the information regarding the construction of the KURAMA database was 
disclosed instead of obtaining written informed consent as previously described19.
Data Collection. Across the study, we used data of ANA which were detected by indirect immunoflu-
orescence with HEp-2 cell lines as substrate at an initial serum dilution of 1:40 using FITC-conjugated goat 
anti-human immunoglobulins. Detection was performed in SRL.Inc or LSI Medience Corporation, both of 
which are representatives of the Japanese largest clinical laboratory testing companies8. For the RA patients in the 
KURAMA cohort, we obtained data of ANA with a data collecting system20 from medical records. For the RA 
patients in the IORRA cohort, we obtained ANA data from the database in which the patients’ clinical informa-
tion were stored every six months. Detailed information of ANA levels in each staining pattern was not available 
in the IORRA cohort. When multiple ANA data were available for a patient, single ANA data was randomly 
chosen.
We also collected information of age, sex, age at onset of RA, RF, ACPA, Steinbrocker’s RA stage, class, DAS 
28, TSS and use of methotrexate and biologic agents from the database in each cohort. The information of 
Steinbrocker’s stage, class, DAS 28 in the RA patients were only available in the KURAMA data18. We analyzed 
the associations between ACA and clinical features especially to find an ACA-specific effect on RA outcome21, 22.
We surveyed complications of PBC, secondary SS23, 24 and the existence of Raynaud’s phenomenon and inter-
stitial pneumonia which were manifestations of SSc25 in the enrolled patients with RA based on the clinical chart 
review. The secondary SS was defined by complication with other rheumatic diseases including RA. The informa-
tion of complications and manifestations were available only in the patients from the KURAMA cohort.
TSS Data. Using conventional X-rays, TSS was scored by an experienced reader (MF) for patients in the 
KURAMA cohort, and two other experienced readers (SY and KY) for patients in the IORRA cohort, according 
to the Sharp/van der Heijde method with a total score range of 0 to 44826. The intraobserver correlation coeffi-
cients for the TSS in the KURAMA and the IORRA cohort were 0.93 and 0.95, respectively and interobserver 
correlation coefficients for the TSS in the IORRA cohort was 0.8527.
HLA-DRB1 Genotyping. In the KURAMA cohort, data of HLA-DRB-1 typed with the WALKFlow system28 
were available for 360 patients among 859 patients with RA. In the IORRA cohort, HLA-DRB1 genotyping data 
by a sequencing-based typing method using the AlleleSEQR HLA-DRB1 typing kit (Abbott, Tokyo, Japan) were 
available for the 481 patients. DRB1*01:01, *04:01, *04:04, *04:05, *04:10, *10:01, *14:02 and *14:06 were clas-
sified as SE which is a five amino acid sequence motif in residues at amino acid position 70–74 of the HLA-DRβ 
chain associated with RA onset and severe joint destruction.
Statistical Analysis. The ANA levels were log-transformed (log2(level/40) + 1) and their distributions were 
compared by Wilcoxon rank sum test between ACA group and each of the other groups based on staining pat-
terns in the healthy volunteers or the RA patients who were positive for ANA. We compared clinical and genetic 
characteristics between ACA-positive and -negative RA patients. We performed Wilcoxon signed-rank test for 
quantitative data, and Pearson’s chi-square test or Fisher’s exact test for binary data. Linear regression analysis 














ACA 94.0 21.0 2.24 0.027 −13.3 4.02 5.59 0.018 −12.9 9.49 1.36 0.17
Table 6. An association study between TSS and ACA. KURAMA, Kyoto University Rheumatoid Arthritis 
Management Alliance; IORRA, Institute of Rheumatology, Rheumatoid arthritis; ACA, anti-centromere 
antibody; RA, rheumatoid arthritis; TSS, total sharp score.
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with response variate of TSS and an independent variable of ACA with covariates of RA duration, gender, age 
and RF was performed by standard least squares. Odds ratios were also calculated with 95% confidence intervals.
The analyses were separately performed for RA patients in each cohort. We also performed the analyses in the 
combined study. Since TSS is influenced by various factors whose distribution was different between the cohorts, 
we put an indicator variable of cohort on TSS analysis in the combined study. We performed power calculation of 
the current study for the HLA analyses with use of ‘Genetics Design’ package of R software29.
Statistical analyses were performed using JMP pro version 12 or R statistical software. Significant level was 
determined by Bonferroni’s correction. When clinical information were available in both the KURAMA and 
IORRA cohorts, we regarded an association as significant only when it showed a consistent association pattern 
with p-value less than 0.05 in each cohort and overall p-value in the combined study less than the significant level.
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